DK0853660T3 - Fremgangsmåde til opbevaring af infektiøse rekombinante virusser, vandig virussuspension og anvendelse som lægemiddel - Google Patents

Fremgangsmåde til opbevaring af infektiøse rekombinante virusser, vandig virussuspension og anvendelse som lægemiddel

Info

Publication number: DK0853660T3
Authority: DK; Denmark
Prior art keywords: aqueous; drug; recombinant viruses; virus suspension; infectious recombinant
Prior art date: 1996-07-16

Application number

DK97933740T

Other languages

English (en)

Inventor

Claude Sene

Original Assignee

Transgene Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-07-16

Filing date

1997-07-15

Publication date

2003-05-05

1997-07-15 Application filed by Transgene Sa filed Critical Transgene Sa

2003-05-05 Application granted granted Critical

2003-05-05 Publication of DK0853660T3 publication Critical patent/DK0853660T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/04—Preserving or maintaining viable microorganisms

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Wood Science & Technology (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Biochemistry (AREA)
Animal Behavior & Ethology (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Virology (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)

DK97933740T 1996-07-16 1997-07-15 Fremgangsmåde til opbevaring af infektiøse rekombinante virusser, vandig virussuspension og anvendelse som lægemiddel DK0853660T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR9608851A FR2751343B1 (fr)	1996-07-16	1996-07-16	Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
PCT/FR1997/001308 WO1998002522A1 (fr)	1996-07-16	1997-07-15	Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament

Publications (1)

Publication Number	Publication Date
DK0853660T3 true DK0853660T3 (da)	2003-05-05

Family

ID=9494078

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK97933740T DK0853660T3 (da)	1996-07-16	1997-07-15	Fremgangsmåde til opbevaring af infektiøse rekombinante virusser, vandig virussuspension og anvendelse som lægemiddel

Country Status (11)

Country	Link
US (2)	US6451256B1 (da)
EP (1)	EP0853660B1 (da)
JP (1)	JP3681401B2 (da)
AT (1)	ATE231549T1 (da)
AU (1)	AU711409B2 (da)
CA (1)	CA2232604C (da)
DE (1)	DE69718612T2 (da)
DK (1)	DK0853660T3 (da)
ES (1)	ES2187798T3 (da)
FR (1)	FR2751343B1 (da)
WO (1)	WO1998002522A1 (da)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20080261289A1 (en) *	1996-12-13	2008-10-23	Schering-Plough Corporation	Compositions comprising viruses and methods for concentrating virus preparations
US6544769B1 (en) *	1996-12-13	2003-04-08	Schering Corporation	Compostions comprising viruses and methods for concentrating virus preparations
US6759050B1 (en)	1998-12-03	2004-07-06	Avigen, Inc.	Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith
JP2002531418A (ja) *	1998-12-03	2002-09-24	アビジェン，インコーポレイテッド	アデノ随伴ウイルスの薬学処方物における使用のための賦形剤、およびそれにより構成される薬学処方物
US6225289B1 (en) *	1998-12-10	2001-05-01	Genvec, Inc.	Methods and compositions for preserving adenoviral vectors
FR2791999B1 (fr) *	1999-04-09	2001-09-07	Aventis Pharma Sa	Composition destinee a la conservation d'adenovirus recombinants infectieux
IL145447A0 (en) *	1999-04-09	2002-06-30	Aventis Pharma Sa	Composition for the preservation of infectious recombinant adenoviruses
EP2420247A1 (en)	2000-03-07	2012-02-22	Merck Sharp & Dohme Corp.	Adenovirus formulations
US7456009B2 (en)	2000-03-07	2008-11-25	Merck & Co., Inc.	Adenovirus formulations
EP1284287A4 (en) *	2000-05-10	2004-10-13	Mitsubishi Pharma Corp	METHOD FOR PRODUCING A VIRUS VECTOR
JP2005517394A (ja)	2001-12-12	2005-06-16	エフエイチフォールディングアンドカンパニーリミテッド	ウイルス保存のための組成物
MXPA04006995A (es) *	2002-01-18	2005-07-13	Schering Ag	Formulaciones estabilizadas de adenovirus.
KR100507794B1 (ko) *	2003-02-11	2005-08-17	한미약품 주식회사	고농도 레트로 바이러스 현탁액 제조 방법
WO2005052116A2 (en) *	2003-11-19	2005-06-09	Merck & Co., Inc.	Preservative-containing virus formulations
EP1780269B1 (en) *	2004-02-23	2009-07-08	Crucell Holland B.V.	Virus purification methods
GB0502661D0 (en) *	2005-02-09	2005-03-16	Stabilitech Ltd	A desiccated product
WO2006108707A1 (en) *	2005-04-11	2006-10-19	Crucell Holland B.V.	Virus purification using ultrafiltration
CN1961961B (zh) *	2005-11-11	2010-05-26	深圳市源兴生物医药科技有限公司	一种药物制剂及其制备方法
US10041049B2 (en)	2008-11-03	2018-08-07	Janssen Vaccines & Prevention B.V.	Method for the production of adenoviral vectors
WO2011098592A1 (en)	2010-02-15	2011-08-18	Crucell Holland B.V.	Method for the production of ad26 adenoviral vectors
EA201390424A1 (ru)	2010-09-20	2013-07-30	Круселл Холланд Б.В.	Терапевтическая вакцинация против активного туберкулеза
WO2012041669A1 (en)	2010-09-27	2012-04-05	Crucell Holland B.V.	Heterologous prime boost vaccination regimen against malaria
EA201390810A1 (ru)	2010-12-02	2013-09-30	Онколитикс Байотек Инк.	Жидкие вирусные составы
MX349294B (es) *	2010-12-02	2017-07-21	Oncolytics Biotech Inc	Formulaciones virales liofilizadas.
ES2582504T3 (es)	2012-03-12	2016-09-13	Crucell Holland B.V.	Lotes de adenovirus recombinantes con extremos alterados
US8932607B2 (en)	2012-03-12	2015-01-13	Crucell Holland B.V.	Batches of recombinant adenovirus with altered terminal ends
US9119813B2 (en)	2012-03-22	2015-09-01	Crucell Holland B.V.	Vaccine against RSV
CA2867950C (en)	2012-03-22	2023-02-21	Crucell Holland B.V.	Vaccine against rsv
WO2014009433A1 (en)	2012-07-10	2014-01-16	Transgene Sa	Mycobacterium resuscitation promoting factor for use as adjuvant
KR20150058152A (ko)	2012-07-10	2015-05-28	트랜스진 에스아이	마이코박테리아 항원 백신
JP6469081B2 (ja)	2013-04-25	2019-02-13	ヤンセンファッシンズアンドプリベンションベーフェーＪａｎｓｓｅｎＶａｃｃｉｎｅｓ＆ＰｒｅｖｅｎｔｉｏｎＢ．Ｖ．	安定化された可溶性融合前ｒｓｖｆポリペプチド
BR112015031509B1 (pt)	2013-06-17	2023-05-09	Janssen Vaccines & Prevention B.V.	Polipeptídeo de fusão (f) do vírus sincicial respiratório (rsv) pré- fusão recombinante e composição que o compreende
KR20160130216A (ko)	2014-01-09	2016-11-10	트랜스진 에스아이	헤테로올리고머 미코박테리아 항원의 융합물
US9721484B2 (en)	2014-06-23	2017-08-01	Humanetics Innovative Solutions, Inc.	Shoulder kit assembly for crash test dummy
CA3190510A1 (en)	2014-07-16	2016-01-21	Transgene Sa	Oncolytic virus for expression of immune checkpoint modulators
US10008130B2 (en)	2014-09-17	2018-06-26	Humanetics Innovative Solutions, Inc.	Omni-directional shoulder assembly for crash test dummy
WO2016131945A1 (en)	2015-02-20	2016-08-25	Transgene Sa	Combination product with autophagy modulator
AU2016249798B2 (en)	2015-04-14	2022-05-26	Janssen Vaccines And Prevention B.V.	Recombinant adenovirus expressing two transgenes with a bidirectional promoter
AU2016289492B2 (en)	2015-07-07	2022-08-11	Janssen Vaccines & Prevention B.V.	Vaccine against RSV
CN107847581B (zh)	2015-07-07	2022-03-22	扬森疫苗与预防公司	稳定化的可溶性融合前rsv f多肽
AU2017248018A1 (en)	2016-04-05	2018-09-27	Janssen Vaccines & Prevention B.V.	Vaccine against RSV
CN109069616A (zh)	2016-04-05	2018-12-21	扬森疫苗与预防公司	稳定化的可溶性融合前rsv f蛋白
EP3455358B1 (en)	2016-05-12	2020-08-26	Janssen Vaccines & Prevention B.V.	Potent and balanced bidirectional promoter
WO2017207480A1 (en)	2016-05-30	2017-12-07	Janssen Vaccines & Prevention B.V.	Stabilized pre-fusion rsv f proteins
CA3027807A1 (en)	2016-06-20	2017-12-28	Janssen Vaccines & Prevention B.V.	Potent and balanced bidirectional promoter
EP3484506A1 (en)	2016-07-14	2019-05-22	Janssen Vaccines & Prevention B.V.	Hpv vaccines
WO2018049261A1 (en)	2016-09-09	2018-03-15	Icellhealth Consulting Llc	Oncolytic virus expressing immune checkpoint modulators
WO2018091680A1 (en)	2016-11-18	2018-05-24	Transgene Sa	Cowpox-based oncolytic vectors
EP3562946B1 (en)	2016-12-28	2021-11-24	Transgene SA	Oncolytic viruses and therapeutic molecules
SG11201906271QA (en)	2017-02-09	2019-08-27	Janssen Vaccines & Prevention Bv	Potent and short promoter for expression of heterologous genes
WO2018210871A1 (en)	2017-05-17	2018-11-22	Janssen Vaccines & Prevention B.V.	Methods and compositions for inducing protective immunity against rsv infection
JP2020519663A (ja)	2017-05-17	2020-07-02	ヤンセンファッシンズアンドプリベンションベーフェーＪａｎｓｓｅｎＶａｃｃｉｎｅｓ＆ＰｒｅｖｅｎｔｉｏｎＢ．Ｖ．	Ｒｓｖ感染に対する防御免疫を誘導するための方法及び組成物
WO2019020543A1 (en)	2017-07-28	2019-01-31	Transgene Sa	ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
EP3681533A1 (en)	2017-09-15	2020-07-22	Janssen Vaccines & Prevention B.V.	Method for the safe induction of immunity against rsv
WO2020011754A1 (en)	2018-07-09	2020-01-16	Transgene	Chimeric vaccinia viruses
WO2020090871A1 (ja)	2018-10-30	2020-05-07	国立大学法人東京大学	がん治療のための腫瘍溶解性ウイルス
WO2021155323A1 (en)	2020-01-31	2021-08-05	Beth Israel Deaconess Medical Center, Inc.	Compositions and methods for preventing and treating coronavirus infection-sars-cov-2 vaccines
US20230175012A1 (en)	2020-03-19	2023-06-08	Trizell Ltd.	Temperature-responsive virus storage system
EP4178605A1 (en)	2020-07-13	2023-05-17	Transgene	Treatment of immune depression
AU2022214006A1 (en)	2021-02-01	2023-09-21	St Phi Therapeutics Co., Ltd.	Targeted protein degradation system and use thereof
KR20230147156A (ko)	2021-02-19	2023-10-20	얀센 백신스 앤드 프리벤션 비.브이.	안정화된 융합 전 rsv fb 항원
WO2023020939A1 (en)	2021-08-17	2023-02-23	Janssen Pharmaceuticals, Inc.	Sars-cov-2 vaccines
WO2023025899A2 (en)	2021-08-26	2023-03-02	Transgene	Delivery system for targeting genes of the interferon pathway
WO2023111725A1 (en)	2021-12-14	2023-06-22	Janssen Pharmaceuticals, Inc.	Sars-cov-2 vaccines
WO2023213764A1 (en)	2022-05-02	2023-11-09	Transgene	Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2023213763A1 (en)	2022-05-02	2023-11-09	Transgene	Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2024003353A1 (en)	2022-07-01	2024-01-04	Transgene	Fusion protein comprising a surfactant-protein-d and a member of the tnfsf
WO2024038175A1 (en)	2022-08-18	2024-02-22	Transgene	Chimeric poxviruses

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2668064B1 (fr) *	1990-10-23	1994-12-16	Transgene Sa	Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.
US5658779A (en) *	1992-03-20	1997-08-19	Ligochem, Inc.	Method of adsorbing viruses from fluid compositions
CA2158935A1 (en) *	1993-10-12	1995-04-20	Chiron Viagene, Inc.	Methods for preserving recombinant viruses
FR2711523B1 (fr) *	1993-10-26	1996-02-16	Transgene Sa	Procédé de préparation d'un aérosol viral.
US5545555A (en) *	1994-07-25	1996-08-13	Microtest, Inc.	Microbial transport media
US5559099A (en) *	1994-09-08	1996-09-24	Genvec, Inc.	Penton base protein and methods of using same
US5616487A (en) *	1994-09-15	1997-04-01	Aastrom Biosciences, Inc.	Stabilized retrovirus compositions
US5932223A (en) *	1996-09-26	1999-08-03	Merck & Co., Inc.	Rotavirus vaccine formulations

1996
- 1996-07-16 FR FR9608851A patent/FR2751343B1/fr not_active Expired - Fee Related
1997
- 1997-07-15 JP JP50569198A patent/JP3681401B2/ja not_active Expired - Lifetime
- 1997-07-15 DK DK97933740T patent/DK0853660T3/da active
- 1997-07-15 US US09/043,187 patent/US6451256B1/en not_active Expired - Lifetime
- 1997-07-15 ES ES97933740T patent/ES2187798T3/es not_active Expired - Lifetime
- 1997-07-15 AU AU36986/97A patent/AU711409B2/en not_active Expired
- 1997-07-15 AT AT97933740T patent/ATE231549T1/de active
- 1997-07-15 WO PCT/FR1997/001308 patent/WO1998002522A1/fr active IP Right Grant
- 1997-07-15 EP EP97933740A patent/EP0853660B1/fr not_active Expired - Lifetime
- 1997-07-15 CA CA002232604A patent/CA2232604C/fr not_active Expired - Lifetime
- 1997-07-15 DE DE69718612T patent/DE69718612T2/de not_active Expired - Lifetime
2002
- 2002-08-15 US US10/218,564 patent/US20030082206A1/en not_active Abandoned

Also Published As

Publication number	Publication date
ATE231549T1 (de)	2003-02-15
DE69718612D1 (de)	2003-02-27
US6451256B1 (en)	2002-09-17
DE69718612T2 (de)	2003-11-06
WO1998002522A1 (fr)	1998-01-22
AU3698697A (en)	1998-02-09
JP2000500026A (ja)	2000-01-11
CA2232604C (fr)	2005-06-28
CA2232604A1 (fr)	1998-01-22
FR2751343A1 (fr)	1998-01-23
US20030082206A1 (en)	2003-05-01
JP3681401B2 (ja)	2005-08-10
ES2187798T3 (es)	2003-06-16
AU711409B2 (en)	1999-10-14
EP0853660A1 (fr)	1998-07-22
EP0853660B1 (fr)	2003-01-22
FR2751343B1 (fr)	1998-12-18

Publication	Publication Date	Title
DK0853660T3 (da)	2003-05-05	Fremgangsmåde til opbevaring af infektiøse rekombinante virusser, vandig virussuspension og anvendelse som lægemiddel
DK1261360T3 (da)	2010-05-03	Casein-afledte peptider og anvendelser deraf i behandling
IL123467A0 (en)	1998-09-24	Methods and compositions for the selective modification of nucleic acids
DK1820853T3 (da)	2011-12-19	Rekombinant influenzavirus til vacciner og genterapi
HUP0202502A2 (hu)	2002-11-28	Virális fertőzőképességet blokkoló peptidek és eljárások ezek alkalmazására
FI961536A0 (fi)	1996-04-04	Menetelmä virusten inaktivoimiseksi polyalkeeniglykolin läsnäollessa samoin kuin siten saatu farmaseuttinen valmiste
WO2005052116A3 (en)	2005-12-22	Preservative-containing virus formulations
ES2114073T3 (es)	1998-05-16	Regeneracion del higado inducida por morfogenes.
DE60009146D1 (de)	2004-04-22	Pharmazeutische zubereitungen zur behandlung von dns viraler infektionen, welche ein schleifendiureticum und ein herzglykosid enthalten
ATE259654T1 (de)	2004-03-15	Pharmazeutische präparate zur bekämpfung oder prophylaxe von mikroorganismen infizierten oberflächen
EA199800526A1 (ru)	1999-04-29	Производные бензимидазола и их применение для лечения вирусных инфекций
ATE310828T1 (de)	2005-12-15	Implantat und vektor zur behandlung von erworbenen krankheiten
ATE303816T1 (de)	2005-09-15	Neue therapeutische verwendung eines eine virale ansteckung modulierendes protein zur verhinderung von abstossung von fremdtransplantaten
ES2062990T3 (es)	1995-01-01	Vacunas, que contienen la proteina f del virus del sida.
DE60040910D1 (de)	2009-01-08	Inaktivierte zytokine zur immunisierung
DK0545991T3 (da)	1999-08-16	Peptider, der blokerer infektioner med human immundefektvirus, og fremgangsmåder til anvendelse deraf
DE50103679D1 (de)	2004-10-21	Biokompatible kolloide mit geringer zelladhäsion und aktiver stabilisierung von blutproteinen
RU98117264A (ru)	2000-06-10	Способ инактивации вируса иммунодефицита человека и других вирусов в плазме крови человека с сохранением функциональной активности белков плазмы крови
NO163654C (no)	1990-06-27	Mikrobobleforloeper i steril, injiserbar enhetsdoseringsform, fremgangsmaate til fremstilling av en vandig suspensjonav mikrobobler og anvendelse av mikrobobleforloeperen for injisering i blodstroemmen hos et levende vesen.